Skip to main content

Table 3 Hazard ratios for risk of mortality in gastric cancer patients receiving postoperative adjuvant chemotherapy (pac) or not according to TIL and TAM status

From: Tumor-infiltrating CD8+ T cells combined with tumor-associated CD68+ macrophages predict postoperative prognosis and adjuvant chemotherapy benefit in resected gastric cancer

   Risk of mortality
Variable No. of patients (TIL positive + TAM negative) vs. others
Entire cohort   401 (100%) HR (95% CI) p value
With PAC 256 (63.8%) 0.466 (0.265–0.821) 0.008
Without PAC 145 (36.2%) 0.543 (0.195–1.515) 0.243
Stage II/III cohort   266 (100%)   
With PAC 226 (85.0%) 0.458 (0.257–0.817) 0.008
Without PAC 40 (15.0%) 0.534 (0.191–1.496) 0.233